Skip to content
Search

Latest Stories

​26 pharmacists removed from PCNI register for non-compliance with CPD

The Pharmaceutical Society of Northern Ireland (PSNI) has removed 26 pharmacists from its register due to statutory non-compliance of Continuing Professional Development (CPD) regulations relating to the CPD year 2020-21.

On the direction of the Interim Registrar of the PSNI, the removal from the Pharmaceutical Chemists in Northern Ireland (PCNI) is effective from August 6.


The removal is processed under Regulation 3(2)b of ‘The Council of the Pharmaceutical Society of Northern Ireland (Continuing Professional Development) Regulations (Northern Ireland) 2012’ as amended.

According to the said regulation, if a registered pharmacist failed to comply with the requirements or conditions of the CPD framework or has made a false declaration about compliance, then the registrar may decide to impose on the registered person a requirement to take one or more remedial measures in connection with the registered person’s CPD; or remove the registered person’s name from the register.

CPD involves the tracking and documenting of skills, knowledge, and experience gained, both formally and informally, beyond any initial education and training. It helps pharmacists to keep their practice and proficiency up to date to maintain standards.

​It is a legal requirement for all registered pharmacists. Every registered pharmacist needs to meet the requirements of Standard 5 of the PSNI’s Code: Professional standards of conduct, ethics, and performance for pharmacists in Northern Ireland – to maintain and develop professional knowledge, skills, and competence.

All registered pharmacists has to make an annual CPD submission and declaration to the Registrar by 31 May or other date, as instructed by the Council of the PSNI, except for those pharmacists who have been granted an exemption by the registrar through the Extenuating Circumstances process.​ ​CPD can be recorded and saved, throughout the CPD year, on the pharmacist’s Membership Online (ROL) account in preparation for CPD submission before the end of the CPD year.

Ellen Lucy Booth, Thomas Kevin Burns, Sergi Casanova Crespo, Clodagh Deirdre Cumiskey, Jacinta Henrietta Madonna Curran, Maureen Elizabeth Alexandra Davison, Ciara Patricia Garvey; Bhavini Pradip Khilosia, Julie Josephine Le Gourrierec, Joyce Wen En Ling, Shee Ween Mooi, Dr Rene Ngenkam, Leah Margaret Nugent, Jarlath Michael O’Hagan, Kevin Peter O’Neill, Samuel Thomas Patterson, Simon Luke Porter, Margarida Crispim Ribeiro, Bernardo Manuel dos Santos Segurado, Yuen Ching So, Mariana Soliman, Rachel Mary Strain, Jie Xi Toh, Merna Toma, Nihar Varu and Sze Ing Wong are the pharmacists who are removed from the PCNI register.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less